ライフサイエンスコーパス: pulmonary disease

1 rstitial lung disease or chronic obstructive pulmonary disease).

2 ing low oxygen delivery (e.g. heart failure, pulmonary disease).

3 sting, predominantly in those with localized pulmonary disease.

4 ilar viral titers in respiratory tissues and pulmonary disease.

5 ausing liver disease and chronic obstructive pulmonary disease.

6 g self-DNA sensing, highlighting its role in pulmonary disease.

7 ontribution of the stroma to inflammation in pulmonary disease.

8 used to treat asthma and chronic obstructive pulmonary disease.

9 sepsis in patients with chronic obstructive pulmonary disease.

10 cerbations of asthma and chronic obstructive pulmonary disease.

11 ors in the patients with chronic obstructive pulmonary disease.

12 nts' quality of life was compromised most by pulmonary disease.

13 ema in participants with chronic obstructive pulmonary disease.

14 arly-onset emphysema and chronic obstructive pulmonary disease.

15 smokers with and without chronic obstructive pulmonary disease.

16 responsible for the global proliferation of pulmonary disease.

17 model for emphysematous chronic obstructive pulmonary disease.

18 s involved in asthma and chronic obstructive pulmonary disease.

19 diseases like asthma and chronic obstructive pulmonary disease.

20 farction, and history of chronic obstructive pulmonary disease.

21 eases as Alzheimer's and chronic obstructive pulmonary disease.

22 except hypertension and chronic obstructive pulmonary disease.

23 -chest CT scans that may uncover unsuspected pulmonary disease.

24 eases such as asthma and chronic obstructive pulmonary disease.

25 ry tuberculosis, excluding those with active pulmonary disease.

26 , smoking, drug use, and chronic obstructive pulmonary disease.

27 tion, and pathogenesis of common age-related pulmonary diseases.

28 uding specialists in infectious diseases and pulmonary diseases.

29 lved in psoriasis, rheumatoid arthritis, and pulmonary diseases.

30 ents with PADs and chronic infection-related pulmonary diseases.

31 icoid receptors (GR) are prescribed to treat pulmonary diseases.

32 le providing improved diagnosis of localized pulmonary diseases.

33 frequent subtypes in the clinics of various pulmonary diseases.

34 adiological findings that overlap with other pulmonary diseases.

35 ldren (1.39, 1.29-1.49), chronic obstructive pulmonary disease (1.70, 1.47-1.97), lung cancer (1.69,

36 ; 95% CI, 1.33 to 2.86), chronic obstructive pulmonary disease (14.2%, vs. 5.6% among those without d

37 (55%), diabetes mellitus (31%), and chronic pulmonary disease (15%) were the most common comorbiditi

38 (21,20.8%), diabetes (18,17.8%), and chronic pulmonary disease (16,15.8%) were the most common coexis

39 the Charlson comorbidity index were chronic pulmonary disease (17.5%, n = 5,513) and diabetes mellit

40 med (30% versus 71%) and less likely to have pulmonary disease (20% vs 57%).

41 ion (6% versus 10%), and chronic obstructive pulmonary disease (4% versus 7%) in patients undergoing

42 ght upper lobes from 12 human donors without pulmonary disease (6 smokers and 6 nonsmokers) were eval

43 Acute pulmonary disease (74%) was the most common clinical syn

44 ry cancers (111 083) and chronic obstructive pulmonary disease (83 593).

45 women more than men with chronic obstructive pulmonary disease, a reduction in the estimated left ven

46 ith clinical outcomes in chronic obstructive pulmonary disease: a systematic review and meta-analysis

47 Chronic obstructive pulmonary disease accounts for 3.2% of all physician off

48 h acute exacerbations of chronic obstructive pulmonary disease (AECOPD) often are prescribed antibiot

49 nd acute exacerbation of chronic obstructive pulmonary disease (AECOPD) represent a major burden of d

50 f acute exacerbations of chronic obstructive pulmonary disease (AECOPD).

51 diac disease (aHR 1.76 [1.08-2.86]), chronic pulmonary disease (aHR 2.94 [1.48-5.84]), higher concent

52 primary lung infection, was more common than pulmonary disease alone.

53 The prevalence of chronic pulmonary disease among inpatients can lead to nonrepres

54 ease (COPD) is the most common noninfectious pulmonary disease among people living with HIV, independ

55 atients with symptomatic chronic obstructive pulmonary disease and a history of exacerbations.Objecti

56 Chronic pulmonary disease and gait abnormalities were more commo

57 TLV-1 infection was strongly associated with pulmonary disease and gait abnormalities.

58 to have diabetes, renal disease, and chronic pulmonary disease and had significantly higher white blo

59 ndent pathological changes and their role in pulmonary disease and impact on siRNA delivery, as well

60 hronic diseases, such as chronic obstructive pulmonary disease and interstitial pulmonary fibrosis.

61 nce of illnesses such as chronic obstructive pulmonary disease and lung cancer, however, their effect

62 1 region corresponded to chronic obstructive pulmonary disease and lung function.Conclusions: This wo

63 l virus (RSV) is an important cause of acute pulmonary disease and one of the last remaining major in

64 proteolysis occurring in chronic obstructive pulmonary disease and other diseases.

65 ng disabilities, such as chronic obstructive pulmonary disease and vision loss.

66 complications, detect any underlying chronic pulmonary disease, and also to characterise complex pneu

67 disease (severe asthma, chronic obstructive pulmonary disease, and bronchiectasis) were subjected to

68 heart failure, dementia, chronic obstructive pulmonary disease, and cirrhosis were statistically more

69 ical outcomes in asthma, chronic obstructive pulmonary disease, and cystic fibrosis; however, its pre

70 scular disease, cancers, chronic obstructive pulmonary disease, and dementia in older age groups and

71 d pulmonary infection, chronic fibrocavitary pulmonary disease, and disseminated coccidioidomycosis (

72 ard to progression of immunodeficiency, sino-pulmonary disease, and neurologic decline.

73 c spells such as asthma, chronic obstructive pulmonary disease, and obstructive sleep apnea (OSA) exh

74 ansient ischemic attack, chronic obstructive pulmonary disease, and peripheral arterial disease were

75 ease, known coronary artery disease, chronic pulmonary disease, and renal failure.

76 s suffering from cancer, chronic obstructive pulmonary disease, and several other chronic diseases.

77 tions, including asthma, chronic obstructive pulmonary disease, and various autoimmune diseases.

78 y disease, congestive heart failure, chronic pulmonary diseases, and obesity.

79 ns such as cancer, diabetes, cardiovascular, pulmonary diseases, and tissue fibrosis.

80 moting recovery from critical illness due to pulmonary disease are foundational goals of the critical

81 The most common species causing pulmonary disease are members of Mycobacterium avium com

82 gests that patients with chronic obstructive pulmonary disease are more likely to have adverse employ

83 based recommendations about treatment of NTM pulmonary disease are provided.

84 lity, ejection fraction, chronic obstructive pulmonary disease, arrhythmia, acute kidney injury, firs

85 neumonia, heart failure, chronic obstructive pulmonary disease, arrhythmia, urinary tract infection,

86 serious diseases such as chronic obstructive pulmonary disease as adults, no specific investigation i

87 ILD) is fast approaching chronic obstructive pulmonary disease as the number one indication for lung

88 dence, cancer diagnosis, chronic obstructive pulmonary disease, ascites, sepsis, smoking, steroid, co

89 and recent evidence for chronic obstructive pulmonary disease-associated kidney injury.

90 gs of humans affected by chronic obstructive pulmonary disease-associated pulmonary hypertension and

91 In humans with chronic obstructive pulmonary disease-associated pulmonary hypertension and

92 ity, we identify mediating pathways in three pulmonary diseases (asthma; bronchopulmonary dysplasia (

93 ases (diabetes mellitus, chronic obstructive pulmonary disease, asthma), shockable rhythm, and steroi

94 tory diseases, including chronic obstructive pulmonary disease, asthma, and cystic fibrosis (CF).

95 s to the pathogenesis of chronic obstructive pulmonary disease, asthma, idiopathic pulmonary fibrosis

96 Pneumonia, acute chronic obstructive pulmonary disease/asthma exacerbation, septicemia, acute

97 nd greater prevalence of chronic obstructive pulmonary disease at recruitment.

98 independent of smoking, chronic obstructive pulmonary disease, BMI, renin-angiotensin-aldosterone sy

99 lity among patients with chronic obstructive pulmonary disease but has not been well studied in asthm

100 chmarks for protection against infection and pulmonary disease by changing the route of vaccine deliv

101 sfusion), comorbidities (chronic obstructive pulmonary disease, cancer, sepsis, ventilator dependence

102 with hematological, sepsis, neurologic, and pulmonary disease categories having the highest odds of

103 ns in a heavy smoker and chronic obstructive pulmonary disease cohort, we confirmed the effects of PI

104 (Genetic Epidemiology of Chronic Obstructive Pulmonary Disease) cohort.Measurements and Main Results:

105 re likely to suffer from chronic obstructive pulmonary disease (COPD 30% vs 9.8%; p = 0.018), and mor

106 vs 24.5%; P < .001) and chronic obstructive pulmonary disease (COPD) (29.8% vs 24.3%; P = .006) at b

107 f acute exacerbations of chronic obstructive pulmonary disease (COPD) advanced by air pollution each

108 Chronic obstructive pulmonary disease (COPD) and asthma remain prevalent hum

109 eases (CLRDs), including chronic obstructive pulmonary disease (COPD) and asthma, are the fourth lead

110 s used for patients with chronic obstructive pulmonary disease (COPD) and chronic hypercapnia.

111 urvival in patients with chronic obstructive pulmonary disease (COPD) and chronic severe daytime hypo

112 with smoking-associated chronic obstructive pulmonary disease (COPD) and from mice chronically expos

113 (NIPPV) with outcomes in chronic obstructive pulmonary disease (COPD) and hypercapnia is uncertain.

114 Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibros

115 Chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibros

116 ppropriate patients with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (

117 in chronic diseases such Chronic Obstructive Pulmonary Disease (COPD) and is associated with exercise

118 ps such as patients with chronic obstructive pulmonary disease (COPD) are poorly understood.

119 Patients with chronic obstructive pulmonary disease (COPD) are susceptible to bacterial in

120 es in symptoms using the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test and St.

121 UMEC/VI in patients with chronic obstructive pulmonary disease (COPD) at risk of future exacerbations

122 ommended for people with chronic obstructive pulmonary disease (COPD) by all major COPD clinical prac

123 spirometric evidence of chronic obstructive pulmonary disease (COPD) by current diagnostic criteria

124 Rationale: Chronic obstructive pulmonary disease (COPD) can develop not only through a

125 drop in FEV(1) >=10% in chronic obstructive pulmonary disease (COPD) candidates was associated with

126 high risk of developing chronic obstructive pulmonary disease (COPD) could lead to implementation of

127 s receive a diagnosis of chronic obstructive pulmonary disease (COPD) each year, and it is the fourth

128 smokers with and without chronic obstructive pulmonary disease (COPD) enrolled in the prospective Gen

129 Rationale: Chronic obstructive pulmonary disease (COPD) exacerbations are prone to nonr

130 RV) is a common cause of chronic obstructive pulmonary disease (COPD) exacerbations.

131 y viral infection causes chronic obstructive pulmonary disease (COPD) exacerbations.

132 Rationale: Chronic obstructive pulmonary disease (COPD) has been associated with numero

133 eath among patients with chronic obstructive pulmonary disease (COPD) has been tested.

134 und Pulmonary imaging of chronic obstructive pulmonary disease (COPD) has focused on CT or MRI measur

135 Background Smokers with chronic obstructive pulmonary disease (COPD) have smaller left ventricles (L

136 ons for exacerbations of chronic obstructive pulmonary disease (COPD) improves exercise capacity and

137 ies such as diabetes and chronic obstructive pulmonary disease (COPD) increase patients' susceptibili

138 iagnose and characterise chronic obstructive pulmonary disease (COPD) into its forms, patterns, and s

139 Chronic obstructive pulmonary disease (COPD) is a common and progressive dis

140 Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous

141 Chronic obstructive pulmonary disease (COPD) is a debilitating lung disease

142 Chronic obstructive pulmonary disease (COPD) is a debilitating lung disease

143 Chronic obstructive pulmonary disease (COPD) is a heterogeneous smoking-rela

144 Chronic obstructive pulmonary disease (COPD) is a lung disorder characterize

145 Chronic obstructive pulmonary disease (COPD) is a major global health proble

146 Chronic Obstructive Pulmonary Disease (COPD) is a prevalent chronic pulmonar

147 Chronic obstructive pulmonary disease (COPD) is a progressive condition of c

148 Chronic obstructive pulmonary disease (COPD) is an inflammatory condition as

149 h acute exacerbations of chronic obstructive pulmonary disease (COPD) is associated with debilitating

150 Chronic obstructive pulmonary disease (COPD) is characterized by frequent ex

151 Chronic obstructive pulmonary disease (COPD) is characterized by persistent

152 xercise in patients with chronic obstructive pulmonary disease (COPD) is not known.

153 Chronic obstructive pulmonary disease (COPD) is one such condition, in which

154 Chronic obstructive pulmonary disease (COPD) is the most common noninfectiou

155 Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of d

156 n assessment, asthma and chronic obstructive pulmonary disease (COPD) management, metabolic rate meas

157 Chronic obstructive pulmonary disease (COPD) may originate in early life and

158 Asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) represents the co

159 3.5%; n = 15), or stable chronic obstructive pulmonary disease (COPD) patients (1.2%; 0.3%-7.4%, n =

160 intolerance is common in chronic obstructive pulmonary disease (COPD) patients.

161 ymphoid organs (TLOs) in chronic obstructive pulmonary disease (COPD) progression.

162 vironmental exposures in chronic obstructive pulmonary disease (COPD) remains inconclusive.

163 ades-long progression of chronic obstructive pulmonary disease (COPD) renders identifying different t

164 Although chronic obstructive pulmonary disease (COPD) risk is strongly influenced by

165 those from patients with chronic obstructive pulmonary disease (COPD) show higher IFN responses to RV

166 smokers with and without chronic obstructive pulmonary disease (COPD) using blood samples from the CO

167 after an exacerbation of chronic obstructive pulmonary disease (COPD) was associated with improved su

168 Rationale: Treatment of chronic obstructive pulmonary disease (COPD) with inhaled corticosteroids (I

169 ary dysplasia (BPD); and chronic obstructive pulmonary disease (COPD)).

170 atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and asthma.

171 al conditions, including chronic obstructive pulmonary disease (COPD), and is associated with increas

172 ch as cancer, arthritis, chronic obstructive pulmonary disease (COPD), and others) are associated wit

173 istress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis (PF).

174 the relationship between chronic obstructive pulmonary disease (COPD), asthma and interstitial lung d

175 ascular accidents (CVA), chronic obstructive pulmonary disease (COPD), asthma, diabetes mellitus (DM)

176 le improved treatment of chronic obstructive pulmonary disease (COPD), asthma, or urinary incontinenc

177 presence and severity of chronic obstructive pulmonary disease (COPD), based on the pulmonary functio

178 d risk stratification in chronic obstructive pulmonary disease (COPD), but few large longitudinal coh

179 okers that might overlap chronic obstructive pulmonary disease (COPD), but studies on the progression

180 with moderate or severe chronic obstructive pulmonary disease (COPD), but these findings have not be

181 Chronic obstructive pulmonary disease (COPD), diagnosed by reduced lung func

182 AATD) is associated with chronic obstructive pulmonary disease (COPD), even among never-smokers.

183 ionale: In patients with chronic obstructive pulmonary disease (COPD), increased activity of neck ins

184 luid of individuals with chronic obstructive pulmonary disease (COPD), when compared to healthy contr

185 An obesity paradox in chronic obstructive pulmonary disease (COPD), whereby overweight/obese indiv

186 ncy ablation therapy for chronic obstructive pulmonary disease (COPD), which durably disrupts parasym

187 Chronic obstructive pulmonary disease (COPD), which is most commonly caused

188 inished in patients with chronic obstructive pulmonary disease (COPD), with mounting evidence support

189 a major risk factor for chronic obstructive pulmonary disease (COPD), yet much of COPD risk remains

190 inished in patients with chronic obstructive pulmonary disease (COPD).

191 nd to be associated with chronic obstructive pulmonary disease (COPD).

192 (1.1%) participants had chronic obstructive pulmonary disease (COPD).

193 armacologic treatment of chronic obstructive pulmonary disease (COPD).

194 patients with asthma and chronic obstructive pulmonary disease (COPD).

195 is altered in asthma and chronic obstructive pulmonary disease (COPD).

196 patients with asthma and chronic obstructive pulmonary disease (COPD).

197 action of roflumilast in chronic obstructive pulmonary disease (COPD).

198 e) are both described in chronic obstructive pulmonary disease (COPD).

199 plasma of subjects with chronic obstructive pulmonary disease (COPD).

200 icosis, lung cancer, and chronic obstructive pulmonary disease (COPD).

201 ma, cystic fibrosis, and chronic obstructive pulmonary disease (COPD).

202 that from patients with chronic obstructive pulmonary disease (COPD).

203 AS locus associated with chronic obstructive pulmonary disease (COPD).

204 e clinical management of chronic obstructive pulmonary disease (COPD).

205 l count in patients with chronic obstructive pulmonary disease (COPD).

206 e acute exacerbations of chronic obstructive pulmonary disease (COPD).

207 on, and heterogeneity of chronic obstructive pulmonary disease (COPD).

208 r for the development of chronic obstructive pulmonary disease (COPD).

209 causing the hallmarks of chronic obstructive pulmonary disease (COPD).

210 ry conditions, including chronic obstructive pulmonary disease (COPD).

211 d acute exacerbations of chronic obstructive pulmonary disease (COPD).

212 rtality in patients with chronic obstructive pulmonary disease (COPD).

213 g clinical datasets from chronic obstructive pulmonary disease (COPD).

214 ding cystic fibrosis and chronic obstructive pulmonary disease (COPD).

215 l fibrillation (AF), and chronic obstructive pulmonary disease (COPD).

216 sociated with asthma and chronic obstructive pulmonary disease (COPD).

217 bronchiectasis (BE), and chronic obstructive pulmonary disease (COPD).

218 a major risk factor for chronic obstructive pulmonary disease (COPD); however, more than 25% of COPD

219 low (PMBF) is reduced in chronic obstructive pulmonary disease (COPD); however, the effect of reduced

220 f breathlessness, higher chronic obstructive pulmonary disease [COPD] prevalence, maternal sepsis, hi

221 lated from patients with chronic obstructive pulmonary disease, COPD.

222 d ozone on characterized chronic obstructive pulmonary disease exacerbations in a regression model ad

223 e only specific therapy for individuals with pulmonary disease from AAT deficiency (AATD).

224 eased risk of asthma and chronic obstructive pulmonary disease has been reported in people living wit

225 ty, diabetes, asthma and chronic obstructive pulmonary disease have become major healthcare and econo

226 ses of diabetes, cancer, chronic obstructive pulmonary disease, heart disease, and death.

227 of myocardial infarction, dementia, chronic pulmonary disease, heart failure, and malignancy were si

228 95% CI, 1.00-1.09), and chronic obstructive pulmonary disease (HR, 1.09; 95% CI, 1.03-1.15) in singl

229 ronary artery disease or chronic obstructive pulmonary disease, hypertension, elderly, systolic heart

230 y disease, and neurologic disorders, but not pulmonary disease, immunocompromise, or hypertension.

231 ities like pneumonia and chronic obstructive pulmonary disease) improved all-case agreement to kappa=

232 This guideline focuses on pulmonary disease in adults (without cystic fibrosis or

233 Due to its severity, pulmonary disease in STAT3-HIES patients requires strict

234 00 premature deaths from chronic obstructive pulmonary disease in the two countries.

235 tatus, hypertension, and chronic obstructive pulmonary disease included in multivariable analysis.

236 professionals who care for patients with NTM pulmonary disease, including specialists in infectious d

237 fungal pathogen capable of causing multiple pulmonary diseases, including invasive aspergillosis, ch

238 Pulmonary disease increases the risk of developing abdom

239 uch as for osteoporosis, chronic obstructive pulmonary disease, interstitial lung disease, and corona

240 Chronic obstructive pulmonary disease is a complicated disease requiring int

241 In particular, pulmonary disease is a leading cause of morbidity and mo

242 Rationale: Cystic fibrosis (CF) pulmonary disease is characterized by chronic infection

243 Chronic obstructive pulmonary disease is characterized by incompletely rever

244 cur as part of the repair process in several pulmonary diseases, it is separate from the unique estab

245 MAC pulmonary disease (MAC-PD) can be chronic, debilitating,

246 in healthy human participants with no active pulmonary disease measured in a negative-pressure room.

247 .69; p<0.001) for clinically defined chronic pulmonary disease, moderate-severe expiratory airflow li

248 y fibrosis (n = 13), and chronic obstructive pulmonary disease (n = 15), were analyzed for inflammati

249 tia (n = 1036), and 3 of chronic obstructive pulmonary disease (n = 441).

250 ompatible with asthma or chronic obstructive pulmonary disease, normal spirometry, and normal airways

251 t criteria for non-tuberculous mycobacterial pulmonary disease (NTM-PD).

252 an impaired immune system, cardiovascular or pulmonary diseases, obesity, diabetes mellitus, and canc

253 exposures to asthma and chronic obstructive pulmonary disease on a population level, but not to othe

254 and more likely to have chronic obstructive pulmonary disease or heart failure.

255 determine whether PGD in chronic obstructive pulmonary disease or interstitial lung disease transplan

256 rol subjects, but not in chronic obstructive pulmonary disease or sarcoidosis.

257 1.29; 95% CI 1.07-1.56; p = 0.008), chronic pulmonary disease (OR 1.24; 95% CI 1.08-1.43; p = 0.003)

258 I, 1.19 to 4.05; P=0.01), asthma and chronic pulmonary disease (OR, 3.09; 95% CI, 1.49 to 6.41; P=0.0

259 oward a protective or pathogenic function in pulmonary disease outcome.

260 Chronic obstructive pulmonary disease (P = 0.043), the cessation duration be

261 hypertension (P = 0.45), chronic obstructive pulmonary disease (P = 0.73), chronic kidney disease (P

262 multivariable analysis, chronic obstructive pulmonary disease (P=0.024), prior use of corticosteroid

263 uding asthma (PAF, 16%); chronic obstructive pulmonary disease (PAF, 14%); chronic bronchitis (PAF, 1

264 ensively drug-resistant pathogen that causes pulmonary disease, particularly in cystic fibrosis (CF)

265 lead to numerous human disorders, especially pulmonary diseases, partly through the induction of oxid

266 Chronic obstructive pulmonary disease patients receiving noninvasive ventila

267 supportive treatment in chronic obstructive pulmonary disease patients.

268 Pulmonary disease (PD) due to nontuberculous mycobacteri

269 t report associating HIV-gp120 genotype to a pulmonary disease phenotype, as we uncovered X4 viruses

270 iver disease (PR=2.2 [2.0,2.4]), and chronic pulmonary disease (PR=1.8 [1.8,1.8]).

271 , sleep apnea, diabetes, chronic obstructive pulmonary disease, previous myocardial infarction (MI),

272 ratory death or nonfatal chronic obstructive pulmonary disease, pulmonary tuberculosis, pneumonia, or

273 without injury (Clinical Chronic Obstructive Pulmonary Disease Questionnaire: median, 0.20; interquar

274 rted breathing (Clinical Chronic Obstructive Pulmonary Disease Questionnaire: median, 1.05; interquar

275 The course of pulmonary disease, radiological and histopathological in

276 n conjunction with antibiotics and restricts pulmonary disease rebound after premature (nonsterilizin

277 Chronic obstructive pulmonary disease refers to a group of diseases that cau

278 ember 1), in determining chronic obstructive pulmonary disease risk and severity is controversial.Obj

279 with moderate or severe chronic obstructive pulmonary disease (risk ratio, 2.89; 95% confidence inte

280 g/m(2)vs <25 kg/m(2) 1.5 [1.3-1.6]), chronic pulmonary disease (RR 1.2 [1.1-1.3]), diabetes (RR 1.4 [

281 In patients with localized pulmonary disease, serum CrAg sensitivity was 23.5% comp

282 algorithm was trained to output a measure of pulmonary disease severity on CXRs (pulmonary x-ray seve

283 PXS scores correlated with radiographic pulmonary disease severity scores assigned to CXRs in th

284 automatically measures radiographic COVID-19 pulmonary disease severity, which can be used to track d

285 bronchiolitis, and exacerbations of chronic pulmonary diseases such as asthma.

286 or reports linking aberrant NET formation to pulmonary diseases, thrombosis, mucous secretions in the

287 Informing the Pathway of Chronic Obstructive Pulmonary Disease Treatment) trial demonstrated a signif

288 Informing the Pathway of Chronic Obstructive Pulmonary Disease Treatment) trial, fluticasone furoate

289 chronic kidney disease, chronic obstructive pulmonary disease, valvular heart disease, tobacco use,

290 patients with asthma or chronic obstructive pulmonary disease, viral infections, including those wit

291 Pulmonary disease was assessed clinically and spirometri

292 ch as obesity, diabetes, asthma, and chronic pulmonary disease were associated with higher risk of de

293 ods: Ten healthy participants with no active pulmonary disease were enrolled.

294 rt disease and asthma or chronic obstructive pulmonary disease were the most common comorbid conditio

295 IV, and 29 patients with chronic obstructive pulmonary disease were used as control subjects.

296 Smoking also causes chronic obstructive pulmonary disease, which is treated with beta-adrenocept

297 All patients with chronic obstructive pulmonary disease who received angiotensin-converting en

298 years or younger without chronic obstructive pulmonary disease who were admitted to our hospital syst

299 sis, smear microscopy insufficiently detects pulmonary disease, with test result reporting taking lon

300 genesis, for example, in chronic obstructive pulmonary disease, yet the mechanisms that retain neutro